Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders
The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.
Lava Therapeutics raises $83M in Series C round for bispecific antibodies
The company plans to start clinical development next year. Its focus is on bispecific antibodies - a form of cancer immunotherapy - that use gamma-delta "surveillance" T cells.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.